NACE 01.61 in FR. Official registry identity and a deliberately broad sector benchmark on one indexed company profile.
A deliberately broad indicative range built from comparable companies with stronger filed or size evidence. It is not a company-specific appraisal, market value, asking price, or offer.
Broad benchmark based on comparable companies in this sector — not a company-specific appraisalCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
This broad public range is a starting point based on governed sector or size evidence. Create a free account to refine it with verified company data and build a five-year outlook.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Operating as a business in NACE sector 01.61, CUMA ANTIGEL is registered in France. The company was founded in 1990, incorporated as a 6316.
CUMA ANTIGEL is listed in French National Business Register (RNE/INPI) under registry number 380537068.
Public registry records place CUMA ANTIGEL in the French NACE 01.61 category.
CUMA ANTIGEL's public range is a deliberately broad p10-p90 sector benchmark based on at least 30 comparable companies with stronger filed or size evidence. It is not a company-specific appraisal, midpoint, sale price, offer, or recommendation.
The benchmark is refreshed from governed Tier A/B peer distributions and is labelled separately from the source facts for CUMA ANTIGEL.
CUMA ANTIGEL was founded in 1990 and is registered with French National Business Register (RNE/INPI), incorporated as a 6316.
CUMA ANTIGEL is registered under NACE 01.61: NACE 01.61. That places the business within the French cluster for this activity.
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for CUMA ANTIGEL may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
